Efficacy Results of Melflufen in Combination with Dexamethasone from an Ongoing Open-Label Phase 2 Study in Patients with Relapsed and RelapsedRefractory Multiple Myeloma (RRMM) Presented at ASH
Oncopeptides AB, a clinical stage company developing a peptidase potentiated therapy – melflufen –
presented clinical results from an ongoing Phase 2 study in patients with relapsed and relapsed
refractory multiple myeloma. The results, presented at the American Society of Hematology, in
Orlando, Florida showed an overall response rate (partial response or better) of 41% and clinical
benefit rate (minimal response or better) of 56% in efficacy evaluable patients. At the date of analysis,
the median progression-free survival was 9.4 months. Melflufen showed promising activity in heavily
pre-treated RRMM patients where conventional therapies have failed and rates were similar across the
different patient refractory status groups (single, double and triple refractory patients).
The results are from a clinical trial being carried out across four centers in Europe (Sweden, Italy, the
Netherlands and Denmark) and two in the USA (Boston, MA and Chapel Hill, NC) and cover; Safety and
tolerability, treatment and disposition, efficacy and baseline characteristics. The results support
Oncopeptides’ belief that melflufen has the potential to provide an alternative when conventional
therapies have failed in RRMM patients.
Melflufen is a peptidase-potentiated therapy and a potent antiangiogenic compound. It triggers rapid,
robust, and irreversible DNA damage and exerts it cytotoxicity through alkylation of DNA.
CEO, Jakob Lindberg commented “These trial results, of melflufen in combination with dexamethasone,
are most encouraging and demonstrate a real benefit to late stage multiple myeloma patients. They show
that melflufen has a meaningful effect on the disease, and has the potential to be a strong building block
in the treatment algorithm of multiple myeloma. I am looking forward to building on these findings to
take melflufen through to the next stage of the clinical program.”
The poster entitled ‘Efficacy of Melflufen, a Peptidase Potentiated Therapy, and Dexamethasone in an
Ongoing Open-Label Phase 2 Study in Patients with Relapsed and Relapsed-Refractory Multiple
Myeloma (RRMM)’ can be downloaded here www.oncopeptides.se
Multiple myeloma is the second most common hematological cancer and worldwide more than 180,000
people are living with the disease, with approximately 86,000 new cases diagnosed annually (ref:
International Agency for Research on Cancer).
About Oncopeptides AB
Oncopeptides is a privately held clinical stage pharmaceutical company developing oncology therapies centered on
Melflufen, Oncopeptides lead drug compound, is a peptidase potentiated therapy in clinical development. Melflufen
is a very potent anti-angiogenic compound that triggers rapid, robust, and irreversible DNA damage and exerts it
cytotoxicity through alkylation of DNA. The peptidase targeting causes melflufen and its metabolites to accumulate in
the diseased cells. This results in targeted delivery of the active moieties to the cancer cells, and thereby better
treatment of the disease.
Orphan Drug Designation for melflufen in the Treatment of Multiple Myeloma has been granted by EMA and FDA
Melflufen is currently undergoing Phase II efficacy studies in patients with relapsed and relapsed-refractory multiple
myeloma. The study is being carried out across six centers; in Sweden, Italy, the Netherlands, Denmark and the US
(two sites) – with Dana Faber Cancer Institute, Boston, MA being the lead investigator site. Oncopeptides is currently
in a Phase II clinical trial with melflufen in patients with relapsed and relapsed-refractory multiple myeloma. The
study is being carried out across six centers; in Sweden, Italy, the Netherlands, Denmark and two sites in the US with
Dana Faber Cancer Institute, Boston, MA being the lead investigator site.
For further information please contact:
Jakob Lindberg CEO
Oncopeptides AB, Stockholm, Sweden
Tel: +46 (0) 705 695 471